Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitors
In conclusion, HDAC3 is potential targets for clinical treatment, and our study provides a new approach for targeted therapy of BRM-negative clear cell RCC.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Kidney Cancer | Pathology | Renal Cell Carcinoma | Study